A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-018240-23